MindRank, an AI-driven drug discovery company, has received FDA Investigational New Drug (IND) application clearance for MRANK-106. MRANK-106 is an orally available dual inhibitor of WEE1 and YES1 kinases, intended to treat various cancers, including pancreatic, small cell lung, ovarian, breast, and colorectal cancers. The upcoming Phase I clinical trial will assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced or metastatic solid tumors.
This IND clearance is a substantial advancement for cancer treatment research. MRANK-106’s dual-targeting mechanism, combined with its preferential distribution in tissues and tumors, addresses limitations of current WEE1 inhibitors by potentially minimizing on-target hematotoxicity and enhancing efficacy. This approach offers a promising new avenue for patients battling these challenging cancers, many of which have limited effective treatment options.
MRANK-106 was developed using MindRank’s AI platforms, Molecule Pro™ and PharmKG™. Preclinical studies indicate the drug exhibits superior efficacy as a single agent and in combination therapies, along with an improved safety profile compared to single-target WEE1 inhibitors. The clinical trial launch, slated for 2025, follows successful preclinical candidate confirmation and represents MindRank’s second clinical-stage pipeline after their GLP-1 program.
The FDA’s clearance signifies a crucial step toward potentially bringing a novel therapeutic option to patients with hard-to-treat cancers. Positive clinical trial results could validate MindRank’s AI-driven drug discovery platform and pave the way for further development and potential approval of MRANK-106, impacting the oncology landscape and offering renewed hope for patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
6 Comments
Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint
3 weeks ago[…] endpoints differed by region. That regional endpoint divergence, while not unusual in global oncology trials, creates exactly the kind of interpretive ambiguity that apparently persisted through the January […]
AI-Designed Drugs Are Reaching Human Trials. Now Comes the Hard Part.
3 weeks ago[…] friction shows up in the enrollment timeline data. According to published benchmarks, Phase 1 oncology trials take an average of 20.49 months to complete enrollment, more than double the 8.58-month average […]
When the Protocol Keeps Changing: What MAMS Trials Actually Cost Sites to Run
3 weeks ago[…] I work with that have run adaptive oncology trials describe the monitoring visit rhythm as fundamentally different from fixed-design studies. […]
Eli Lilly’s Five-Day Ultimatum: How Pharma Is Weaponizing 340B Deadlines to Squeeze Hospital Trial Networks
3 weeks ago[…] ultimatum are not abstract billing entities. They are the same institutions hosting Phase II oncology trials, running investigational drug services, and managing investigational product through the same […]
When Gilead Cuts 108 Jobs at Arcellx, Your Trial Feels It Before You Know Why
3 weeks ago[…] activation delays in complex oncology trials already cost the industry far more than most sponsors budget for. Industry data puts the rate of […]
BIOMEDE Missed Its Primary Endpoint — And Still Changed Pediatric CNS Trial Design Forever
3 weeks ago[…] is the counterintuitive truth buried in the BIOMEDE data. Sponsors have treated negative Phase 2 oncology trials as program killers. The more accurate read is that a null Phase 2 with mandatory molecular […]
Comments are closed.